|
Most recently Hassan was a founding member and vice president of sales of Reckitt Benckiser pharmaceuticals where he was responsible for the initial commercial planning and launch of the highly successful new innovative treatment for opiate addiction- Suboxone (buprenorphine). Reckitt Benckiser is a $25 billion global enterprise. Mr. Hassan has also held management positions at Parke-Davis/Pfizer where he was responsible for annual revenues in excess of $180 million per year and at Bayer Pharmaceuticals. | 